Latest studies
- Ongoing, recruitingTherapeutic use (Phase IV)
I4V-MC-JAJA (RA-BRIDGE): A Randomized, Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients with Rheumatoid Arthritis
This study looks at how safe and effective a medicine called baricitinib is for people with rheumatoid arthritis, compared to other common treatments. It will see how long it takes for a blood clot to happen. This is a long-term study that will last over five years.
Rheumatoid ArthritisAustria - Ongoing, recruitingTherapeutic confirmatory (Phase III)
INCB 18424-320: A phase 3, double-blind, randomised, vehicle-controlled, efficacy and safety study of ruxolitinib cream in participants with Prurigo Nodularis. Topical ruxolitinib evaluation in Prurigo Nodularis (TRuE-PN2)
This study is testing a new cream for people with very itchy skin lumps called Prurigo Nodularis. It wants to see if the cream, called ruxolitinib, can reduce itching compared to a cream without any medicine in it. The study aims to find out how well it works and if it's safe.
Prurigo NodularisAustria - Ongoing, recruitingTherapeutic exploratory (Phase II)
An open-label sleep laboratory study of efficacy and safety of piromelatine in a well-defined population of patients with idiopathic (isolated) Rapid Eye Movement Behavior Disorder (iRBD).
This study is testing a new medicine, piromelatine, for people with a sleep problem called REM Behavior Disorder (RBD). Researchers want to see if it's safe and helps reduce unusual movements and actions during sleep.
idiopathic (isolated) Rapid Eye Movement Behavior DisorderAustria - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab plus Investigational Agents in Combination with Etoposide and Cisplatin or Carboplatin for the First-Line Treatment of Participants with Extensive-Stage Small Cell Lung Cancer (KEYNOTE-B99)
This study is looking at new ways to treat advanced small cell lung cancer for the first time. It combines Pembrolizumab with other medications to see how well they work together and if they are safe.
First-line treatment of participants with extensive-stage small cell lung cancerAustria - Ongoing, recruitingPhase III and phase IV (Integrated)
MEMENTO-A Phase 3b/4 Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to assess the impact on Myocardial Structure with Cardiac Magnetic Resonance Imaging (CMR)
This study is looking at a new medicine called mavacamten for adults with a heart condition called obstructive hypertrophic cardiomyopathy (HCM). It aims to see if the medicine can reduce the thickness of the heart walls and the size of the heart's upper chambers.
Symptomatic Obstructive Hypertrophic CardiomyopathyAustria - Ongoing, recruitingTherapeutic exploratory (Phase II)
A 12-Month, Randomized, Controlled, Open-Label, Dose Escalation Study Evaluating Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of an Anti-CD2 Monoclonal Antibody, TCD601(siplizumab) Compared to Anti-Thymocyte Globulin (rATG), as Induction Therapy in de novo Renal Transplant Recipients
This study looks at a new medicine called TCD601 (siplizumab) for people who have recently had a kidney transplant. It compares TCD601 to a standard treatment to see if it's safe and how well it helps prevent the body from rejecting the new kidney.
Renal TransplantationAustria - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy with Nivolumab + Relatlimab Fixed-dose Combination versus Nivolumab Monotherapy after Complete Resection of Stage III-IV Melanoma
This study looks at a new combination treatment for advanced melanoma that has been removed by surgery. It compares two drugs given together (nivolumab and relatlimab) against nivolumab alone, to see if the combination can help prevent the cancer from coming back.
Participants with completely resected Stage III or Stage IV melanomaAustria - Ongoing, recruitingTherapeutic confirmatory (Phase III)
An open-label, prospective Phase III clinical study to compare polatuzumab vedotin plus rituximab, ifosfamide, carboplatin and etoposide (Pola-R-ICE) with rituximab, ifosfamide, carboplatin and etoposide (R-ICE) alone as salvage therapy in patients with primary refractory or relapsed diffuse large B-cell lymphoma (DLBCL)
This study is for adults with a type of lymphoma called DLBCL that has come back or not responded to earlier treatment. It compares two treatments: a standard one (R-ICE) and a new one (Pola-R-ICE) to see which is better at stopping the cancer from growing.
Adult patients with relapsed or primary refractory DLBCLAustria - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A randomised double-blind placebo-controlled clinical trial investigating the effect and safety of oral semaglutide in subjects with early Alzheimer´s disease (EVOKE)
This study is testing a new medicine called semaglutide for people with early Alzheimer's disease. Researchers want to see if it can help improve memory and thinking, and how safe it is to use.
Mild cognitive impairment (MCI) or mild dementiaboth of the Alzheimer’s typeAustria - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
A study to test how a new long-acting insulin works in the body of patients with type 2 diabetes during exercise and prolonged fasting.
This study is looking at a new, long-acting insulin for people with type 2 diabetes. Researchers want to see how it works in the body during exercise and when you haven't eaten for a longer time. It's an early-stage study to understand the new insulin better.
Type 2 diabetesAustria - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of Baxdrostat in Participants with Uncontrolled Hypertension on Two or More Medications including Participants with Resistant Hypertension
This study is testing a new drug called Baxdrostat for people whose high blood pressure isn't controlled by their current medicines. It aims to see if Baxdrostat helps lower blood pressure and if it's safe to use, compared to a dummy pill.
Uncontrolled hypertension (uTHN) defined as blood pressure that remains higher than goal levels despite patients being treated with 2 anti-hypertensive agentsincluding a diuretic. Resistant hypertension (rHTN) defined as blood pressure that remains higher than goal levels despite the use of at least 3 anti hypertensive drugs of different classes at maximum tolerated doseincluding a diuretic.Austria - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A randomised double-blind placebo-controlled clinical trial investigating the effect and safety of oral semaglutide in subjects with early Alzheimer´s disease (EVOKE plus)
This study is looking at a new tablet, semaglutide, to see if it can help people with early Alzheimer's disease. Researchers want to know if it's safe and if it can slow down changes in memory and thinking over about two years.
Mild cognitive impairment (MCI) or mild dementiaboth of the Alzheimer’s typeAustria - Ongoing, recruitingPhase II and Phase III (Integrated)
INTERVENTIONAL PLATFORM STUDY INVESTIGATING THE IMPACT OF DIGITAL HEALTH SOLUTIONS ON HEALTH OUTCOMES AND HEALTH-CARE RESOURCE UTILIZATION IN PARTICIPANTS RECEIVING SYSTEMIC TREATMENT IN CLINICAL PRACTICE (ORIGAMA)
This study looks at how digital health tools can help people with certain types of lung and liver cancer. It checks if these tools improve symptoms and help patients get treatment at home, potentially improving care and reducing hospital visits.
Cohort A: • Metastatic non-small cell lung carcinoma (mNSCLC) • Extensive-stage small-cell lung carcinoma (ES-SCLC) • Advanced or unresectable hepatocellular carcinoma (HCC) Cohort B: • Resected Stage IIB-IIIB (early-stageper the UICC/AJCC staging system8th edition) non-small cell lung carcinoma (NSCLC)Austria - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression (FORTITUDE-102)
This study is for people with advanced stomach or gut cancer that has a specific genetic marker called FGFR2b. It tests a new drug, bemarituzumab, combined with usual treatments (chemotherapy and nivolumab) to see if it works better than usual treatments alone.
Gastric and Gastroesophageal Junction Cancer With FGFR2b OverexpressionAustria - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
A Phase 1/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors
This study is looking at a new treatment for advanced cancers. We're testing a new drug, BMS-986016, alone and with an existing cancer drug, Nivolumab, to see how safe and effective they are. It's a key first step in understanding these potential new treatments.
Neoplasms by siteAustria - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A randomized, double-blind, placebo-controlled, 2-arm Phase III study to assess efficacy and safety of xevinapant and radiotherapy compared to placebo and radiotherapy for demonstrating improvement of disease-free survival in participants with resected squamous cell carcinoma of the head and neck, who are at high-risk for relapse and are ineligible for high-dose cisplatin
This study looks at a new medicine called xevinapant, given with radiotherapy, for people who have had surgery for head and neck cancer. It compares this treatment to radiotherapy with a dummy medicine, to see if xevinapant helps prevent the cancer from coming back.
Resected squamous cell carcinoma of the head and neckAustria - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
A study to assess how radium-223 moves through the patients with prostate cancer receiving radium-223 dichloride treatment.
This study looks at how a medicine called radium-223 moves through the bodies of men with prostate cancer who are receiving this treatment. It helps doctors understand how the drug works and is processed by the body.
Prostate cancerAustria - Ongoing, recruitingTherapeutic confirmatory (Phase III)
An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900, an Oral Plasma Kallikrein Inhibitor, for On-demand Treatment of Angioedema Attacks in Adolescent and Adult Patients with Hereditary Angioedema Type I or II A Pharmacokinetic Subtrial in Adolescent Patients with Hereditary Angioedema Type I or II Participating in the KVD900-302 Trial
This study looks at how safe a medicine called KVD900 is when used long-term for swelling attacks in people with Hereditary Angioedema (HAE) Type 1 or 2. It also checks how the body handles the medicine in teenagers.
Hereditary Angioedema Type I or IIAustria - Ongoing, recruitingTherapeutic confirmatory (Phase III)
Effects of Plasma Exchange with Human Serum Albumin 5% (PE-A 5%) on Short-term Survival in Subjects with Acute-On-Chronic Liver Failure" (ACLF) at High Risk of Hospital Mortality
This study looks at a treatment called plasma exchange with human albumin for people with serious liver problems. We want to see if this treatment helps people live longer and get better, compared to standard care alone.
Subjects with cirrhosis with ACLF-1bACLF-2or ACLF-3a detected either at admission or during hospitalizationAustria - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase III, Double-Blinded, Multicenter, Randomized Study Evaluating the Efficacy and Safety of Neoadjuvant Treatment with Atezolizumab or Placebo in Combination with Platinum-Based Chemotherapy in Patients With resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer
This study is testing a new way to treat early-stage lung cancer before surgery. It combines standard chemotherapy with a new drug called Tecentriq, or a dummy drug, to see if it helps patients live longer and stay cancer-free.
Early-Stage Resectable Non-small cell lung cancer (NSCLC)Austria - Ongoing, recruitingPhase II and Phase III (Integrated)
IMPAHCT: A Phase 2b/3, Randomized, Double-Blind, Placebo-Controlled, 24-Week Dose Ranging and Confirmatory Study to Evaluate the Safety and Efficacy of AV-101 in Patients with Pulmonary Arterial Hypertension (PAH)
This study is looking into a new treatment, AV-101, for Pulmonary Arterial Hypertension (PAH), a condition affecting the lungs and heart. It aims to see if the treatment is safe and effective by comparing it to a dummy medicine.
Pulmonary Arterial Hypertension (PAH)Austria - Ongoing, recruitingTherapeutic exploratory (Phase II)
(22423 NIRVANA) A randomized, parallel-group treatment, Phase 2, double-blind pilot study to investigate the efficacy and safety of elinzanetant compared with placebo for treatment of sleep disturbances associated with menopause
This study is testing a new medicine, elinzanetant, for women experiencing sleep problems during menopause. Researchers want to see if it helps improve sleep and if it's safe compared to a dummy pill.
Sleep disturbances associated with menopauseAustria - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
Study with healthy volunteers to investigate the safety, tolerability, blood concentration and some effects of various amounts of the pharmaceutical substance SR-878
This study is looking for healthy volunteers to test a new medicine called SR-878. Researchers want to see if it's safe, how well people tolerate it, and how much of it stays in the blood. They'll also check for any early effects.
Healthy VolunteersAustria - Ongoing, recruitingTherapeutic confirmatory (Phase III)
IMPAHCT-FUL: A Long-Term Extension, Multi-Center Safety Study of AV-101 in Subjects With Pulmonary Arterial Hypertension (PAH) Who Have Completed Study AV-101-002
This study looks at the long-term safety of a new medicine, AV-101, for people with pulmonary arterial hypertension (PAH). It's for those who have already tried AV-101 in a previous study and aims to learn more about how well it's tolerated over time.
Pulmonary Arterial Hypertension (PAH)Austria - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy, safety, and tolerability of dexpramipexole administered orally for 52 weeks in participants with severe eosinophilic asthma (EXHALE-3)
This study looks at a new medicine called dexpramipexole for severe asthma. It wants to see if the medicine can reduce asthma flare-ups and improve breathing over 52 weeks. Researchers will compare it to a dummy medicine to see if it works and is safe.
Severe eosinophilic asthmaAustria - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 2b/3 Study of Safety and Efficacy of AMX0035 in Progressive Supranuclear Palsy (ORION)
This study, called ORION, is testing a new drug called AMX0035 for Progressive Supranuclear Palsy (PSP). Researchers want to see if the drug is safe and helps slow down the disease's progression. It's a late-stage trial, hoping to show clear benefits.
Progressive Supranuclear PalsyAustria - Ongoing, recruitingTherapeutic use (Phase IV)
A prospective, randomized, double-blind, controlled trial on the application of a 10%-lidocain spray prior to the insertion of a peripheral intra-venous catheter in female adults
This study looks at whether a numbing spray can reduce pain when putting in an IV drip (a small tube in your vein) in adult women. We're hoping to find a simple way to make this common procedure less uncomfortable.
PainAustria - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase II, Double-blind, Placebo-controlled, Randomized, Dose-ranging, Parallel Group Study to Evaluate the Safety and Efficacy of PHA-022121 Administered Orally for Prophylaxis Against Angioedema Attacks in Patients with Hereditary Angioedema due to C1-Inhibitor Deficiency (Type I or Type II)
This study is testing a new medicine, PHA-022121, for people with hereditary angioedema (HAE) Type 1 or 2. We want to see if it can help prevent swelling attacks. Participants will take either the new medicine or a dummy pill, and we'll compare how many attacks they have.
Hereditary angioedema due to C1-Inhibitor Deficiency (Type I or Type II)Austria - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3 Study of Pembrolizumab in Combination with Carboplatin/Taxane (Paclitaxel or Nab-paclitaxel) Followed by Pembrolizumab with or without Maintenance Olaparib in the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
This study is looking at new ways to treat a type of lung cancer that has spread. It combines standard chemotherapy with a newer drug, pembrolizumab, and sometimes involves another drug, olaparib, to see if this mix works better.
Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)Austria - Ongoing, recruitingHuman Pharmacology (Phase I)- First administration to humans
A study to learn how safe and tolerable odronextamab and cemiplimab are in adult patients with B-cell malignancies
This study is looking at a new treatment for certain blood cancers, called B-cell non-Hodgkin lymphoma. It's the very first time these medicines are being given to people. Researchers want to see how safe they are and how well people tolerate them.
B-Cell Non-Hodgkin’s Lymphoma (B-NHL)Austria - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Ulcerative Colitis
This study is testing a new medicine called Rosnilimab for people with moderate to severe Ulcerative Colitis. Researchers want to see if it helps reduce symptoms and improve gut health compared to a dummy treatment, and if it's safe to use.
Ulcerative ColitisAustria - Ongoing, recruitingTherapeutic confirmatory (Phase III)
CA209-8HW A Phase 3 Randomized Clinical Trial of Nivolumab alone, Nivolumab in Combination with Ipilimumab, or Investigator’s Choice Chemotherapy in Participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Metastatic Colorectal Cancer
This study looks at new drug combinations for advanced bowel cancer that has specific genetic changes (MSI-H or dMMR). It compares them to standard chemotherapy to see which is better at stopping the cancer from growing.
Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient Metastatic Colorectal Cancer (dMMR)Austria - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke
This study looks at a new medicine called Evolocumab to see if it can lower the chance of serious heart problems like heart attacks or strokes in people at high risk who haven't had them before. It compares Evolocumab to a dummy medicine.
Adults at high risk of cardiovascular events without prior MI or stroke.Austria - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants with Relapsed or Refractory Multiple Myeloma (RRMM) - ALUMMINATE RRMM
This study is testing a new medicine, Alnuctamab, for people in the UK with multiple myeloma whose cancer has come back or isn't responding to other treatments. Researchers want to see if Alnuctamab works better and is safer than current treatments, aiming to stop the cancer from growing for longer.
Relapsed and/or Refractory Multiple MyelomaAustria - Ongoing, recruitingTherapeutic use (Phase IV)
PHARMACOKINETICS OF CEFEPIME AFTER INTRAPERITONEAL ADMINISTRATION VIA CYCLER-THERAPY IN APD PATIENTS WITHOUT PERITONITIS
This study looks at how a specific antibiotic, Cefepime, works in people on peritoneal dialysis for severe kidney disease. We want to understand how the body handles the medicine when it's given through the dialysis machine to help treat or prevent infections, but not if they currently have an active infection.
CKD 5Peritoneal DialysisAustria - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2a multi-center, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Burfiralimab (hzVSF-v13) added to disease-modifying antirheumatic drugs in patient with moderate to severe Rheumatoid Arthritis
This study is testing a new medicine, Burfiralimab, for people with moderate to severe rheumatoid arthritis. We want to see if it helps reduce joint pain and swelling when added to their usual arthritis medicines. Participants will receive either the new medicine or a dummy treatment.
rheumatoid arthritisAustria - Ongoing, recruitingTherapeutic confirmatory (Phase III)
Circulating tumour DNA based decision for adjuvant treatment in colon cancer stage II evaluation (CIRCULATE) AIO-KRK-0217.
This study looks at whether a blood test called ctDNA can help doctors decide on treatment for people with stage II bowel cancer. It compares giving chemotherapy based on this test to just watching and waiting, to see which approach leads to better outcomes.
colon cancer stage IIrectal cancer stage IIAustria - Ongoing, recruitingTherapeutic confirmatory (Phase III)
I4V-MC-JAIP: A Phase 3, Multicenter, Randomized, Double blind, Placebo controlled, Parallel group, Outpatient Study Evaluating the Pharmacokinetics, Efficacy, and Safety of Baricitinib in Pediatric Patients with Moderate-to-Severe Atopic Dermatitis
This study is looking at a new medicine called Baricitinib for children and teenagers with moderate to severe eczema. It wants to see if the medicine is safe and effective in helping their skin get better, compared to a dummy pill.
Atopic DermatitisAustria - Ongoing, recruitingTherapeutic confirmatory (Phase III)
"A PHASE 3, MULTICENTER, MULTINATIONAL, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY OF CC-93538 IN ADULT AND ADOLESCENT SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS"
This study looks at the long-term safety of a medicine called Cendakimab (also known as CC-93538) for adults with a condition called Eosinophilic Esophagitis. It checks for side effects over a long period to make sure the treatment is safe for people to use.
Eosinophilic esophagitisAustria - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Multicenter, Randomized, Double-Masked, Vehicle-Controlled Study to Assess the Safety and Efficacy of SYD-101 Ophthalmic Solution for the Treatment of Myopia in Children
This study is testing a new eye drop called SYD-101 to see if it can slow down the worsening of short-sightedness (myopia) in children. Researchers want to know if it's safe and how well it works compared to a dummy eye drop over two years.
MyopiaAustria - Ongoing, recruitingTherapeutic exploratory (Phase II)
CLL-Frail - A prospective, multicenter phase II trial of acalabrutinib in very old (≥80y) or frail CLL-Patients
This study looks at a medicine called Calquence for older or weaker patients with a type of blood cancer called CLL. It's for people who haven't had treatment before or whose cancer has come back. We want to see how well the medicine works after about six months.
treatment-naïve or relapsed/refractory chronic lymphocytic leukemiaAustria - Ongoing, recruitingTherapeutic exploratory (Phase II)
ABCSG 45: A prospective, open, randomized, phase II study of carboplatin/olaparib in the pre-operative treatment of patients with triple-negative primary breast cancer which exhibit the features of positive homologous recombination deficiency (HRD) status
This study looks at a new combination treatment for a specific type of early breast cancer. It compares giving a drug called olaparib with carboplatin before surgery, with a standard chemotherapy. The aim is to see if the new treatment shrinks the cancer more effectively.
Early invasive triple negative breast cancer with positive HRD status (acc. to Myriad mychoice© test)Austria - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3 Study of Pembrolizumab in Combination with Pemetrexed/Platinum (Carboplatin or Cisplatin) Followed by Pembrolizumab and Maintenance Olaparib vs Maintenance Pemetrexed in the First-Line Treatment of Participants with Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC)
This study is looking at new ways to treat advanced lung cancer. It combines standard chemotherapy with newer drugs, pembrolizumab and olaparib, to see if this mix works better than current treatments in slowing down cancer growth and helping people live longer and feel better.
Stage IV lung cancer conditionAustria - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2a, Randomized, Placebo-controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of PTC518 in Subjects with Huntington’s Disease
This study is testing a new medicine, PTC518, for Huntington's Disease. Researchers want to see if it's safe, how well it works, and what dose might be best. Participants will receive either the medicine or a dummy pill.
Huntington’s DiseaseAustria - Ongoing, recruitingTherapeutic confirmatory (Phase III)
BMS CV027-031, A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adults with Symptomatic Nonobstructive Hypertrophic Cardiomyopathy
This study is looking at a new medicine called Mavacamten for adults with a heart condition called non-obstructive hypertrophic cardiomyopathy. It aims to see if the medicine can make people feel better and improve their exercise ability over 48 weeks.
Non-obstructive Hypertrophic CardiomyopathyAustria - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, multicenter, open-label, randomized study to evaluate the efficacy and safety of fedratinib compared to best available therapy in subjects with DIPSS - intermediate or high-risk primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis and previously treated with ruxolitinib
This study is comparing a new medicine, fedratinib, with other common treatments for people with a type of bone marrow disorder called myelofibrosis. It's for patients whose myelofibrosis has been treated before with another drug called ruxolitinib. We want to see how well fedratinib shrinks the spleen.
Primary myelofibrosispost-polycythemia vera myelofibrosisor post-essential thrombocythemia myelofibrosisAustria - Ongoing, recruitingTherapeutic use (Phase IV)
Effect of Dupilumab on nasal epithelial barrier function in patients with Chronic Rhinosinusitis with nasal polyps (CRSwNP) – an exploratory pilot study
This study looks at how a medicine called Dupixent affects the lining of the nose in people with long-term sinus problems and polyps. It aims to see if the medicine helps strengthen this lining and reduce their symptoms.
Chronic rhinosinusitis with nasal polypsChronic rhinosinusitis without nasal polypsAustria - Ongoing, recruitingTherapeutic exploratory (Phase II)
CLEAR-AKI: A multi-center, randomized, double blinded, placebo-controlled, four arm, parallel-group, dose-finding phase 2b study to investigate the safety and efficacy of TIN816 via a single intravenous infusion in the treatment of participants associated with sepsis- associated acute kidney injury (SA-AKI)
This study is looking into a new medicine, TIN816, for people who have kidney damage caused by sepsis. Researchers want to see if it's safe and helps the kidneys work better. Some people will get the medicine, others a dummy treatment.
Sepsis associated acute kidney injuryAustria - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma
This study is looking at a new way to treat follicular lymphoma, a type of cancer. It compares a drug called Ibrutinib with a standard treatment, Rituximab. The aim is to see if adding Ibrutinib helps people live longer without their cancer getting worse.
Follicular LymphomaAustria - Ongoing, recruitingTherapeutic exploratory (Phase II)
A 14-Week Phase 2b, RandomizEd, Double-BLind, Dose-Ranging Study to Determine the PharmacokInetics, Efficacy, Safety, and Tolerability of TEV-48574 in Adult PatiEnts with Moderate to Severe Ulcerative Colitis or Crohn’s Disease (RELIEVE UCCD)
This study is testing a new medicine called TEV-48574 for adults with moderate to severe Crohn's disease or ulcerative colitis. It aims to see how well it works, if it's safe, and how the body handles it, comparing it to a dummy medicine.
Crohn’s diseaseUlcerative colitisAustria